Your session is about to expire
← Back to Search
Amivantamab + Capmatinib for Non-Small Cell Lung Cancer (METalmark Trial)
METalmark Trial Summary
This trial is testing a combination of two drugs to treat non-small cell lung cancer. The first part of the trial is to find the best dose of the combination, and the second part is to see how well the combination works.
METalmark Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowMETalmark Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.METalmark Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have been diagnosed with Stage IV non-small cell lung cancer that cannot be surgically removed.I have brain metastases needing more steroids recently to manage symptoms.I cannot take pills due to issues with my stomach or intestines.I have or might have a lung condition not caused by an infection.My brain metastases have been treated, are stable, and I've had no symptoms for over 2 weeks.I have had cancer before, but it won't affect this study's treatment.My cancer pain is not managed and I haven't had palliative radiotherapy in the last week.I am fully active or restricted in physically strenuous activity but can do light work.
- Group 1: Phase 1 (Combination Dose Selection)
- Group 2: Phase 2 (Dose Expansion)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
In how many different places can people participate in this clinical trial?
"There are 13 hospitals conducting this trial, such as VCU Medical Center in Richmond, University of Alabama at Birmingham, Comprehensive Cancer Center in Birmingham and Providence Portland Medical Center in Portland."
Does Amivantamab have the FDA's backing?
"Amivantamab was given a score of 2 by our analysts because, although there is evidence that the drug is safe, there is no data demonstrating that it is effective."
Are we still receiving participants for this experiment?
"The clinical trial mentioned is not presently enrolling patients, as noted on clinicaltrials.gov. This study was posted on November 28th, 2020 and updated recently on the 9th of November, 2020. Although this specific study isn't recruiting at this time, there are 1,394 other trials that are still recruiting patients."
What are the goals that researchers hope to achieve with this trial?
"The primary outcome of this study, which will be evaluated over about Up to 2 years 1 month is to Phase 1: Number of Participants with Adverse events (AEs) by Severity. Secondary objectives include Phase 2: Overall Survival (OS) which is defined as OS is defined as the time from the date of administration of the first study treatment until the date of death due to any cause., Phase 1: Number of Participants with Abnormalities in Clinical Laboratory Parameters which is defined as Number of participants with abnormalities in clinical laboratory parameters (serum chemistry, hematology, coagulation, serology, and urinalysis)"
Share this study with friends
Copy Link
Messenger